Orbital gallium-67 scintigraphy in Graves' ophthalmopathy: A disease activity parameter that predicts the therapeutic response to immunosuppressive treatment

Thyroid

Volumn 15, Issue 4, 2005, Pages 358-363

  Konuk, Onur ^a,b   Atasever, Tamer ^a   Unal, Mehmet ^a   Ayvaz, Goksun ^a   Yetkin, Ilhan ^a   Cakir, Nuri ^a   Arslan, Metin ^a   Hasanreisoglu, Berati ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; GALLIUM CITRATE GA 67; METHYLPREDNISOLONE;

ADULT; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ACTIVITY; ENDOCRINE OPHTHALMOPATHY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; AGED; FEMALE; GALLIUM RADIOISOTOPES; GRAVES DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; ORBIT;

EID: 18744382477     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2005.15.358     Document Type: Conference Paper

References (18)

1. Bartalena L, Pinchera A, Marcocci C 2000 Management of Graves' ophthalmopathy. Reality and perspectives. Endocr Rev 21:168-99.
2. Mourits MPh, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R 1989 Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: A novel approach. Br J Ophthalmol 73:639-644.
3. Konuk O, Atasever T, Unal M, Ayvaz G, Yetkin I, Cakir N, Arslan M, Hasanreisoglu B 2002 Orbital gallium-67 scintigraphy in Graves' ophthalmopathy. Thyroid 12:603-608.
4. Werner SC 1977 Modification of the classification of the eye changes of Graves' disease: Recommendations of the ad hoc committee of the American Thyroid Association. J Clin Endocrinol Metab 44:203-204.
5. Prummel MF, Bakker A, Wiersinga WM, Baldeschi L, Mourits MP, Kendall-Taylor P, Perros P, Neoh C, Dickinson AJ, Lazarus JH, Lane CM, Heufelder AE, Kahaly GJ, Pitz S, Orgiazzi J, Hullo A, Pinchera A, Marcocci C, Sartini MS, Rocchi R, Nardi M, Krassas GE, Halkias A 2003 Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: The first Europian Group on Graves Orbitopathy experience. Eur J Endocrinol 148:491-495.
6. Donaldson SS, Bagshaw MA, Kriss JP 1973 Supervoltage orbital radiotherapy for Graves' ophthalmopathy. J Clin Endocrinol Metab 37:276-285.
7. Gerding MN, van der Zant FM, van Royen EA, Koornneef L, Krenning AP, Wiersinga WM, Prummel MF 1999 Octreotide scintigraphy is a disease activity parameter in Graves' ophthalmopathy. Clin Endocrinol 50:373-379.
8. Mourits MPh, Prummel MF, Wiersinga WM, Koornneef L 1994 Measuring eye movements in Graves' ophthalmopathy. Ophthalmology 101:1341-1346.
9. Wiersinga WM, Prummel MF 2000 An evidence-based approach to the treatment of Graves' ophthalmopathy. Endocrin Metab North Am 29:297-319.
10. Burch HB, Wartofsky L 1993 Graves' Ophthalmopathy: Current concepts regarding pathogenesis and management. Endocr Rev 14:747-793.
11. Prummel MF, Suttorp-Schulten MSA, Wiersinga WM, Erbeek AM, Mourits MPH, Koornneef L 1993 A new ultrasonographic method to detect disease activity and predict response to immunosuppressive treatment in Graves' ophthalmopathy. Ophthalmology 100:556-561.
12. Utech CJ, Khatibnia U, Winter PF, Wulle KG 1995 MR T2 relaxation time for the assessment of retrobulbar inflammation in Graves' ophthalmopathy. Thyroid 5:185-193.
13. Postema PTE, Krenning EP, Wijngaarde R, Kooy PPM, Oei HY, van den Bosch WA, Reubi JC, Wiersinga WM, Hooijkaas H, van der Loos T, Poublon RML, Lamberts SWJ, Hennemann G 1994 (111 In-DTPA-D-Phe1) octreotide scintigraphy in thyroidal and orbital Graves' disease: A parameter of disease activity. J Clin Endocrinol Metab 79:1845-1851.
14. Wiersinga WM, Gerding MN, Prummel MF, Krenning EP 1998 Octreotide scintigraphy in thyroidal and orbital Graves' disease. Thyroid 8:433-436.
15. Krassas GE, Doumas A, Kaltsas T, Halkias A, Pontikides N 1999 Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease. Thyroid 9:47-52.
16. Doumas AS, Krassas GE, Kaltsas T, Pontikides N 2003 Imaging somatostatin receptor activity in patients with active thyroid eye disease using Tc-99m depreotide. Clin Nucl Med 28:439-440.
17. Gerding MN, Prummel MF, Wiersinga WM 2000 Assessment of disease activity in Graves' ophthalmopathy by orbital ultrasonography and clinical parameters. Clin Endocrinol 52:641-646.
18. Hiromatsu Y, Kojima K, Ishisaka N 1992 Role of magnetic resonance imaging in thyroid associated ophthalmopathy: Its predictive value for therapeutic outcome of immunosuppressive therapy. Thyroid 2:299-305.